Publication:
SEOM clinical guideline for the management of cutaneous melanoma (2020).

dc.contributor.authorMajem, M
dc.contributor.authorManzano, J L
dc.contributor.authorMarquez-Rodas, I
dc.contributor.authorMujika, K
dc.contributor.authorMuñoz-Couselo, E
dc.contributor.authorPérez-Ruiz, E
dc.contributor.authorde la Cruz-Merino, L
dc.contributor.authorEspinosa, E
dc.contributor.authorGonzalez-Cao, M
dc.contributor.authorBerrocal, A
dc.date.accessioned2024-02-19T15:26:17Z
dc.date.available2024-02-19T15:26:17Z
dc.date.issued2021-03-02
dc.description.abstractMelanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
dc.format.number5es_ES
dc.format.page948-960es_ES
dc.format.volume23es_ES
dc.identifier.doi10.1007/s12094-020-02539-9
dc.identifier.e-issn1699-3055es_ES
dc.identifier.journalClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexicoes_ES
dc.identifier.otherhttp://hdl.handle.net/10668/17259
dc.identifier.pubmedID33651321es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18276
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAdjuvant treatment metastatic treatment
dc.subjectMelanoma
dc.subjectStaging
dc.subject.meshBiopsy
dc.subject.meshBrain Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshLymph Node Excision
dc.subject.meshMedical Oncology
dc.subject.meshMelanoma
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshNeoplasm Staging
dc.subject.meshProto-Oncogene Proteins B-raf
dc.subject.meshRadiotherapy, Adjuvant
dc.subject.meshSkin Neoplasms
dc.subject.meshSocieties, Medical
dc.subject.meshSpain
dc.titleSEOM clinical guideline for the management of cutaneous melanoma (2020).
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files